The present invention relates to the field of in vitro methods for identifying a subject suitable for treatment with a combination of immunotherapy and chemotherapy by identifying a specific genetic signature in a biological sample from said subject as well as diagnostic devices for performing said method.
1. An in vitro method for identifying a subject suitable for treatment with a combination of immunotherapy and chemotherapy, comprising determining the absence of a somatic mutation in at least two of the genes EGFR, KMT2C, APC, ERBB3, and HNF1A, and/or the absence of a germline mutation in PBRM1 in a biological sample from the subject, wherein the subject is afflicted with cancer. 2. The method of claim 1, wherein the absence of a somatic mutation in at least two of the genes EGFR, KMT2C, APC, ERBB3, and HNF1A, and/or the absence of a germline mutation in PBRM1 in a biological sample from the subject indicates that said subject is more likely to respond to a treatment with a combination of immunotherapy and chemotherapy than a subject not having said absence. 3. The method of any one of the preceding claims, comprising determining the absence of a somatic mutation in at least three, at least four, or in all of the genes EGFR, KMT2C, APC, ERBB3, and HNF1A, and/or the absence of a germline mutation in PBRM1. 4. The method of any one of the preceding claims, wherein the germline mutation in PBRM1 is variant c.1443+60T>G. 5. The method of any one of the preceding claims, wherein the cancer comprises lung cancer, preferably non-small cell lung cancer (NSCLC). 6. The method of any one of the preceding claims, wherein the immunotherapy comprises a therapy using PD-1 or PD-L1 antagonists, preferably wherein said PD-1 or PD-L1 antagonists are selected from Pembrolizumab, Nivolumab and/or Atezolizumab, Ipilimumab, Durvalumab. 7. The method of any one of the preceding claims, wherein the chemotherapy comprises the use of a chemotherapeutic agent selected from paclitaxel, carboplatin, docetaxel, oxaliplatin, cisplatin, or any combination thereof. 8. The method of any one of the preceding claims, wherein the biological sample comprises a tumor tissue biopsy, a liquid biopsy, blood, serum, plasma, genomic DNA, circulating tumor cells, ctDNA, cfDNA, or any combination thereof. 9. A diagnostic device/kit for determining the absence of a somatic mutation in at least one of the genes EGFR, KMT2C, APC, ERBB3 and HNF1A, and/or the absence of a germline mutation in PBRM1 in a biological sample from a subject afflicted with cancer. 10. The diagnostic device of claim 9, wherein the absence of a somatic mutation in at least two of the genes EGFR, KMT2C, APC, ERBB3 and HNF1A, and/or the absence of a germline mutation in PBRM1 in a biological sample from the subject indicates that said subject is more likely to respond to a combination of immunotherapy and chemotherapy than a subject not having said absence. 11. The diagnostic device of any one of claims 9 or 10, wherein the cancer is lung cancer, preferably non-small cell lung cancer (NSCLC). 12. The diagnostic device of any one of claims 9 to 11, wherein the immunotherapy comprises a therapy using PD-1 or PD-L1 antagonists, preferably selected from Pembrolizumab, Nivolumab and/or Atezolizumab, Ipilimumab, Durvalumab. 13. The diagnostic device of any one of claims 9 to 12, wherein the biological sample comprises a tumor tissue biopsy, a liquid biopsy, blood, serum, plasma, circulating tumor cells, ctDNA, cfDNA, or any combination thereof. 14. The diagnostic device of any one of claims 9 to 13, wherein the germline mutation in PBRM1 is variant c.1443+60T>G. 15. In vitro use of the absence of a somatic mutation in at least two of the genes EGFR, KMT2C, APC, ERBB3 and HNF1A, or the absence of a germline mutation in PBRM1, preferably the germline mutation c.1443+60T>G in PBRM1, as biomarkers in determining whether an anticancer effect is likely to be produced in a cancer by a combination of immunotherapy and chemotherapy, in particular immunotherapy with PD-1 or PD-L1 antagonists.